|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Guo HX, Wang Q, Wang C, Yin QC, Huo HZ and
Yin BH: Secular trends in gastric and esophageal cancer
attributable to dietary carcinogens from 1990 to 2019 and
projections until 2044 in China: Population-based study. JMIR
Public Health Surveill. 9:e484492023. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maomao C, He L, Dianqin S, Siyi H, Xinxin
Y, Fan Y, Shaoli Z, Changfa X, Lin L, Ji P and Wanqing C: Current
cancer burden in China: Epidemiology, etiology, and prevention.
Cancer Biol Med. 19:1121–1138. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Y, Yan Q, Fan C, Mo Y, Wang Y, Li X,
Liao Q, Guo C, Li G, Zeng Z, et al: Overview and countermeasures of
cancer burden in China. Sci China Life Sci. 66:2515–2526. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qiu H, Cao S and Xu R: Cancer incidence,
mortality, and burden in China: A time-trend analysis and
comparison with the United States and United Kingdom based on the
global epidemiological data released in 2020. Cancer Commun (Lond).
41:1037–1048. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sekiguchi M, Oda I, Matsuda T and Saito Y:
Epidemiological trends and future perspectives of gastric cancer in
Eastern Asia. Digestion. 103:22–28. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li GZ, Doherty GM and Wang J: Surgical
management of gastric cancer: A review. JAMA Surg. 157:446–454.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong J, Tsai Y, Novick D, Hsiao FCH, Cheng
R and Chen JS: The economic burden of advanced gastric cancer in
Taiwan. BMC Health Serv Res. 17:6632017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xu H and Li W: Early detection of gastric
cancer in China: Progress and opportunities. Cancer Biol Med.
19:1622–1628. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Machlowska J, Baj J, Sitarz M, Maciejewski
R and Sitarz R: Gastric cancer: Epidemiology, risk factors,
classification, genomic characteristics and treatment strategies.
Int J Mol Sci. 21:40122020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen D, Fu M, Chi L, Lin L, Cheng J, Xue
W, Long C, Jiang W, Dong X, Sui J, et al: Prognostic and predictive
value of a pathomics signature in gastric cancer. Nat Commun.
13:69032022. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao R, Gong L and Dong D: Pathological
diagnosis and prognosis of gastric cancer through a multi-instance
learning method. EBioMedicine. 73:1036712021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Chen T and Fang JY: Burden of
gastrointestinal cancers in China from 1990 to 2019 and projection
through 2029. Cancer Lett. 560:2161272023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li H, Zhang H, Zhang H, Wang Y, Wang X and
Hou H; Global Health Epidemiology Reference Group, : Survival of
gastric cancer in China from 2000 to 2022: A nationwide systematic
review of hospital-based studies. J Glob Health. 12:110142022.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lordick F, Carneiro F, Cascinu S, Fleitas
T, Haustermans K, Piessen G, Vogel A and Smyth EC; ESMO Guidelines
Committee. Electronic address, : simpleclinicalguidelines@esmo.org:
Gastric cancer: ESMO clinical practice guideline for diagnosis,
treatment and follow-up. Ann Oncol. 33:1005–1020. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guan WL, He Y and Xu RH: Gastric cancer
treatment: Recent progress and future perspectives. J Hematol
Oncol. 16:572023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ajani JA, D'Amico TA, Bentrem DJ, Chao J,
Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al:
Gastric cancer, version 2.2022, NCCN clinical practice guidelines
in oncology. J Natl Compr Canc Netw. 20:167–192. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kobayashi D and Kodera Y: Intraperitoneal
chemotherapy for gastric cancer with peritoneal metastasis. Gastric
Cancer. 20 (Suppl 1):S111–S121. 2017. View Article : Google Scholar
|
|
20
|
Boilève J, Touchefeu Y and Matysiak-Budnik
T: Clinical management of gastric cancer treatment regimens. Curr
Top Microbiol Immunol. 444:279–304. 2023.PubMed/NCBI
|
|
21
|
Patel TH and Cecchini M: Targeted
therapies in advanced gastric cancer. Curr Treat Options Oncol.
21:702020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li K, Zhang A, Li X, Zhang H and Zhao L:
Advances in clinical immunotherapy for gastric cancer. Biochim
Biophys Acta Rev Cancer. 1876:1886152021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kawakami H and Okamoto I: MET-targeted
therapy for gastric cancer: The importance of a biomarker-based
strategy. Gastric Cancer. 19:687–695. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joshi SS and Badgwell BD: Current
treatment and recent progress in gastric cancer. CA Cancer J Clin.
71:264–279. 2021.PubMed/NCBI
|
|
25
|
Doi M, Murai I, Kunisue S, Setsu G, Uchio
N, Tanaka R, Kobayashi S, Shimatani H, Hayashi H, Chao HW, et al:
Gpr176 is a Gz-linked orphan G-protein-coupled receptor that sets
the pace of circadian behaviour. Nat Commun. 7:105832016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakagawa S, Nguyen Pham KT, Shao X and Doi
M: Time-restricted G-protein signaling pathways via GPR176,
Gz, and RGS16 Set the pace of the master circadian clock
in the suprachiasmatic nucleus. Int J Mol Sci. 21:50552020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamaguchi Y, Murai I, Takeda M, Doi S,
Seta T, Hanada R, Kangawa K, Okamura H, Miyake T and Doi M:
Nmu/Nms/Gpr176 triple-deficient mice show enhanced light-resetting
of circadian locomotor activity. Biol Pharm Bull. 45:1172–1179.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang J, Peng W, Ji J, Peng C, Wang T, Yang
P, Gu J, Feng Y, Jin K, Wang X and Sun Y: GPR176 promotes cancer
progression by interacting with G protein GNAS to restrain cell
mitophagy in colorectal cancer. Adv Sci (Weinh). 10:e22056272023.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yun WJ, Xue H, Yang N, Xiao LJ, Sun HZ and
Zheng HC: Oncogenic roles of GPR176 in breast cancer: A potential
marker of aggressiveness and a potential target of gene therapy.
Clin Transl Oncol. 25:3042–3056. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yun WJ, Li J, Yin NC, Zhang CY, Cui ZG,
Zhang L and Zheng HC: The promoting effects of GPR176 expression on
proliferation, chemoresistance, lipogenesis and invasion of
oesophageal cancer. J Cancer Res Clin Oncol. 149:14641–14655. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang Y, Gu X, Zhu F, Li Y, Huang Y and Ju
S: High expression of GPR176 predicts poor prognosis of gastric
cancer patients and promotes the proliferation, migration, and
invasion of gastric cancer cells. Sci Rep. 13:93602023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ni L, Chen S, Liu J, Li H, Zhao H, Zheng
C, Zhang Y, Huang H, Huang J, Wang B and Lin C: GPR176 is a
biomarker for predicting prognosis and immune infiltration in
stomach adenocarcinoma. Mediators Inflamm. 2023:71235682023.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
East MP, Laitinen T and Asquith CRM:
PIP5K1A: A potential target for cancers with KRAS or TP53
mutations. Nat Rev Drug Discov. 19:4362020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding T, Ji J, Zhang W, Liu Y, Liu B, Han
Y, Chen C and Yu L: The phosphatidylinositol
(4,5)-bisphosphate-Rab35 axis regulates migrasome formation. Cell
Res. 33:617–627. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin M and Wang Y: The role of PIP5K1A in
cancer development and progression. Med Oncol. 39:1512022.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sarwar M, Syed Khaja AS, Aleskandarany M,
Karlsson R, Althobiti M, Ødum N, Mongan NP, Dizeyi N, Johnson H,
Green AR, et al: The role of PIP5K1α/pAKT and targeted inhibition
of growth of subtypes of breast cancer using PIP5K1α inhibitor.
Oncogene. 38:375–389. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu WT, Li YJ, Feng AZ, Li L, Huang T, Xu
AD and Lyu J: Data mining in clinical big data: The frequently used
databases, steps, and methodological models. Mil Med Res.
8:442021.PubMed/NCBI
|
|
38
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Somerville TDD, Wiseman DH, Spencer GJ,
Huang X, Lynch JT, Leong HS, Williams EL, Cheesman E and
Somervaille TC: Frequent derepression of the mesenchymal
transcription factor gene FOXC1 in acute myeloid leukemia. Cancer
Cell. 28:329–342. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Glaviano A, Foo ASC, Lam HY, Yap KCH,
Jacot W, Jones RH, Eng H, Nair MG, Makvandi P, Geoerger B, et al:
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies
in cancer. Mol Cancer. 22:1382023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wong SHM, Fang CM, Chuah LH, Leong CO and
Ngai SC: E-cadherin: Its dysregulation in carcinogenesis and
clinical implications. Crit Rev Oncol Hematol. 121:11–22. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jim MA, Pinheiro PS, Carreira H, Espey DK,
Wiggins CL and Weir HK: Stomach cancer survival in the United
States by race and stage (2001–2009): Findings from the CONCORD-2
study. Cancer. 123 (Suppl 24):S4994–S5013. 2017. View Article : Google Scholar
|
|
44
|
Budginaite E, Kloft M, van Kuijk SMJ,
Canao PA, Kooreman LFS, Pennings AJ, Magee DR, Woodruff HC and
Grabsch HI: The clinical importance of the host anti-tumour
reaction patterns in regional tumour draining lymph nodes in
patients with locally advanced resectable gastric cancer: A
systematic review and meta-analysis. Gastric Cancer. 26:847–862.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xia X, Zhang Z, Zhu C, Ni B, Wang S, Yang
S, Yu F, Zhao E, Li Q and Zhao G: Neutrophil extracellular traps
promote metastasis in gastric cancer patients with postoperative
abdominal infectious complications. Nat Commun. 13:10172022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang ZY and Ge HY: Micrometastasis in
gastric cancer. Cancer Lett. 336:34–45. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv
L, Liu J, Xu Y, Shen Y and Yang M: Noncoding RNAs in gastric
cancer: Implications for drug resistance. Mol Cancer. 19:622020.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yuan L, Xu ZY, Ruan SM, Mo S, Qin JJ and
Cheng XD: Long non-coding RNAs towards precision medicine in
gastric cancer: Early diagnosis, treatment, and drug resistance.
Mol Cancer. 19:962020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Willems L, Tamburini J, Chapuis N, Lacombe
C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in
cancer: New data on targeted therapies. Curr Oncol Rep. 14:129–138.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhou X, Li T, Xie H, Huang H, Yang K, Zeng
X and Peng T: HBV-induced N6 methyladenosine modification of PARP1
enhanced AFB1-related DNA damage and synergistically contribute to
HCC. Ecotoxicol Environ Saf. 298:1182542025. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li H, Prever L, Hirsch E and Gulluni F:
Targeting PI3K/AKT/mTOR signaling pathway in breast cancer. Cancers
(Basel). 13:35172021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhou X, Luo J, Xie H, Wei Z, Li T, Liu J,
Liao X, Zhu G and Peng T: MCM2 promotes the stemness and sorafenib
resistance of hepatocellular carcinoma cells via hippo signaling.
Cell Death Discov. 8:4182022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
57
|
Almhanna K, Strosberg J and Malafa M:
Targeting AKT protein kinase in gastric cancer. Anticancer Res.
31:4387–4392. 2011.PubMed/NCBI
|
|
58
|
Zhou XD, Chen HX, Guan RN, Lei YP, Shu X,
Zhu Y and Lv NH: Protein kinase B phosphorylation correlates with
vascular endothelial growth factor A and microvessel density in
gastric adenocarcinoma. J Int Med Res. 40:2124–2134. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shi J, Yao D, Liu W, Wang N, Lv H, Zhang
G, Ji M, Xu L, He N, Shi B and Hou P: Highly frequent PIK3CA
amplification is associated with poor prognosis in gastric cancer.
BMC Cancer. 12:502012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kobayashi I, Semba S, Matsuda Y, Kuroda Y
and Yokozaki H: Significance of Akt phosphorylation on tumor growth
and vascular endothelial growth factor expression in human gastric
carcinoma. Pathobiology. 73:8–17. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang Y, Kwok-Shing Ng P, Kucherlapati M,
Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R,
Hadjipanayis A, et al: A Pan-cancer proteogenomic atlas of
PI3K/AKT/mTOR pathway alterations. Cancer Cell. 31:820–832.e3.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Janku F, Yap TA and Meric-Bernstam F:
Targeting the PI3K pathway in cancer: Are we making headway? Nat
Rev Clin Oncol. 15:273–291. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Okkenhaug K, Graupera M and Vanhaesebroeck
B: Targeting PI3K in cancer: Impact on tumor cells, their
protective stroma, angiogenesis, and immunotherapy. Cancer Discov.
6:1090–1105. 2016. View Article : Google Scholar : PubMed/NCBI
|
